This inventor holds 1 USPTO granted patent. Top assignee: Gubra A/s. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Morten Lundh: Innovator in Amylin Receptor Potency
Introduction
Morten Lundh is a notable inventor based in Hoersholm, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target amylin receptors. His work is crucial in addressing medical conditions such as obesity, NASH, and diabetes.
Latest Patents
Morten Lundh holds a patent for "HAManalogues with improved amylin receptor (hAMY3R) potency." This invention relates to hAManalogues that exhibit enhanced potency for the amylin receptor (hAMY3R-EC≤250 pM). The hAManalogues are primarily based on the sequence of the human adrenomedullin fragment hAM. They are selective agonists for the amylin receptor, maintaining good physical stability and offering potential therapeutic applications.
Career Highlights
Morten Lundh is associated with Gubra A/S, a company focused on innovative solutions in the field of metabolic diseases. His work at Gubra A/S has positioned him as a key player in the development of new therapeutic agents.
Collaborations
Morten has collaborated with notable colleagues, including Kristoffer Tobias Gustav Rigbolt and Esben Matzen Bech. Their combined expertise contributes to the advancement of research and development in their field.
Conclusion
Morten Lundh's innovative work in amylin receptor potency exemplifies the impact of targeted pharmaceutical research. His contributions are paving the way for new treatments for significant medical conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile